Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer

Oncogene

Volumn 33, Issue 28, 2014, Pages 3707-3716

  Roy, S S ^a   Gonugunta, V K ^a   Bandyopadhyay, A ^b   Rao, M K ^b,c   Goodall, G J ^d   Sun, L Z ^b,c   Tekmal, R R ^a,c   Vadlamudi, R K ^a,c  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; MICRORNA 141; MICRORNA 200; MICRORNA 200A; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROLINE GLUTAMIC ACID AND LEUCINE RICH PROTEIN 1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CELL INVASION; CELL MIGRATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENOME ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CO-REPRESSOR PROTEINS; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE 2; HUMANS; MICE; MICE, NUDE; MICRORNAS; NEOPLASM METASTASIS; TRANSCRIPTION FACTORS;

EID: 84904265560     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.332     Document Type: Article

References (42)

1. Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 2012; 11: 479-497.
2. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12: 895-904. (Pubitemid 44175140)
3. Stetler-Stevenson WG, Liotta LA, Kleiner Jr DE. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993; 7: 1434-1441. (Pubitemid 24003262)
4. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070. (Pubitemid 41161233)
5. Khoshnaw SM, Green AR, Powe DG, Ellis IO. MicroRNA involvement in the pathogenesis and management of breast cancer. J Clin Pathol 2009; 62: 422-428.
6. Wang L, Wang J. MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene 2012; 31: 2499-2511.
7. Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 2009; 69: 7495-7498.
8. Shi M, Liu D, Duan H, Shen B, Guo N. Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev 2010; 29: 785-799.
9. Saha RS, Vadlamudi RK. Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer 2012; 2012: 654698.
10. OMalley BW. Molecular biology. Little molecules with big goals. Science 2006; 313: 1749-1750.
11. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/ corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006; 20: 1405-1428. (Pubitemid 43830648)
12. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M et al. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 2005; 56(Suppl 1): 10-2010-20.
13. Mann M, Krishnan S, Vadlamudi RK. Emerging significance of estrogen cancer coregulator signaling in breast cancer. Minerva Ginecol 2012; 64: 75-88.
14. OMalley BW. Coregulators: from whence came these "master genes". Mol Endocrinol 2007; 21: 1009-1013.
15. Vadlamudi RK, Kumar R. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal 2007; 5:e004.
16. Chakravarty D, Tekmal RR, Vadlamudi RK. PELP1: A novel therapeutic target for hormonal cancers. IUBMB Life 2010; 62: 162-169.
17. Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RR, Vadlamudi RK. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res 2007; 67: 5505-5512. (Pubitemid 46997292)
18. Roy S, Chakravarty D, Cortez V, De MK, Bandyopadhyay A, Ahn JM et al. Significance of PELP1 in ER-negative breast cancer metastasis. Mol Cancer Res 2012; 10: 25-33.
19. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601. (Pubitemid 351627379)
20. Nair BC, Nair SS, Chakravarty D, Challa R, Manavathi B, Yew PR et al. Cyclindependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res 2010; 70: 7166-7175.
21. Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P et al. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res 2011; 17: 2250-2259.
22. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68: 7846-7854.
23. Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200- dependent pathway in mice. J Clin Invest 2011; 121: 1373-1385.
24. Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011; 128: 1327-1334.
25. Choi YB, Ko JK, Shin J. The transcriptional corepressor, PELP1, recruits HDAC2 and masks histones using two separate domains. J Biol Chem 2004; 279: 50930-50941. (Pubitemid 40017832)
26. Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C et al. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res 2012; 14: R108.
27. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelialmesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009; 119: 1438-1449.
28. OMalley BW, Kumar R. Nuclear receptor coregulators in cancer biology. Cancer Res 2009; 69: 8217-8222.
29. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-589. (Pubitemid 351772923)
30. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68: 3645-3654.
31. Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 2000; 36(13 Spec No): 1607-1620. (Pubitemid 30616365)
32. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M et al. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 2001; 3: 30-37. (Pubitemid 32114829)
33. Qin L, Liao L, Redmond A, Young L, Yuan Y, Chen H et al. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol 2008; 28: 5937-5950.
34. Qin L, Liu Z, Chen H, Xu J. The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res 2009; 69: 3819-3827.
35. Habashy HO, Powe DG, Rakha EA, Ball G, Macmillan RD, Green AR et al. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat 2009; 120: 603-612.
36. Nair SS, Guo Z, Mueller JM, Koochekpour S, Qiu Y, Tekmal RR et al. Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol 2007; 21: 613-624.
37. Chakravarty D, Nair SS, Santhamma B, Nair BC, Wang L, Bandyopadhyay A et al. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res 2010; 70: 4092-4101.
38. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW et al. p53 regulates epithelialmesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13: 317-323.
39. Nair SS, Nair BC, Cortez V, Chakravarty D, Metzger E, Schule R et al. PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep 2010; 11: 438-444.
40. Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT et al. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 2010; 5: e10365.
41. Goldshaid L, Rubinstein E, Brandis A, Segal D, Leshem N, Brenner O et al. Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors. Breast Cancer Res 2010; 12: R29.
42. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 2005; 7: R444-R454.